Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer

NCT01222780 is registered in ClinicalTrials.gov with Acrotech Biopharma Inc. as lead sponsor.

NCT NCT01222780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01222780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
Lead sponsor
Acrotech Biopharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2010
Completion date
December 31, 2014
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors, leukemia, lymphoma, neuroblastoma, sarcoma, wilms tumor